JPH0244286B2 - - Google Patents
Info
- Publication number
- JPH0244286B2 JPH0244286B2 JP57111859A JP11185982A JPH0244286B2 JP H0244286 B2 JPH0244286 B2 JP H0244286B2 JP 57111859 A JP57111859 A JP 57111859A JP 11185982 A JP11185982 A JP 11185982A JP H0244286 B2 JPH0244286 B2 JP H0244286B2
- Authority
- JP
- Japan
- Prior art keywords
- alkaline
- magnesium
- component
- aspirin
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 70
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 66
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 47
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 35
- 239000002775 capsule Substances 0.000 claims description 34
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 23
- 239000002552 dosage form Substances 0.000 claims description 22
- 239000011777 magnesium Substances 0.000 claims description 22
- 229910052749 magnesium Inorganic materials 0.000 claims description 22
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 22
- 239000001095 magnesium carbonate Substances 0.000 claims description 22
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 22
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 20
- 239000000395 magnesium oxide Substances 0.000 claims description 19
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 19
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 19
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 19
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 19
- 230000001754 anti-pyretic effect Effects 0.000 claims description 16
- 239000002221 antipyretic Substances 0.000 claims description 16
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 16
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 15
- 239000000347 magnesium hydroxide Substances 0.000 claims description 15
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 229940125716 antipyretic agent Drugs 0.000 claims description 11
- 238000000748 compression moulding Methods 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 5
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 230000003139 buffering effect Effects 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 45
- 239000000463 material Substances 0.000 description 14
- 235000010216 calcium carbonate Nutrition 0.000 description 10
- 235000014380 magnesium carbonate Nutrition 0.000 description 9
- 235000012245 magnesium oxide Nutrition 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 235000012254 magnesium hydroxide Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229910019440 Mg(OH) Inorganic materials 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 235000001055 magnesium Nutrition 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- -1 polydimethylsiloxane Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- WFXURHIXPXVPGM-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 WFXURHIXPXVPGM-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960005008 doxylamine succinate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960003956 phenindamine tartrate Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27801181A | 1981-07-01 | 1981-07-01 | |
US278011 | 1981-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS588020A JPS588020A (ja) | 1983-01-18 |
JPH0244286B2 true JPH0244286B2 (xx) | 1990-10-03 |
Family
ID=23063318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57111859A Granted JPS588020A (ja) | 1981-07-01 | 1982-06-30 | 緩衝されたアスピリン製品用に適する圧縮成形されたアルカリ性成分 |
Country Status (9)
Country | Link |
---|---|
JP (1) | JPS588020A (xx) |
KR (1) | KR880001933B1 (xx) |
AU (1) | AU551510B2 (xx) |
BE (1) | BE893729A (xx) |
CA (1) | CA1165242A (xx) |
GR (1) | GR75990B (xx) |
NZ (1) | NZ200695A (xx) |
PH (1) | PH18787A (xx) |
PT (1) | PT75168B (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4102629A1 (de) * | 1991-01-30 | 1992-08-06 | Bayer Ag | Pharmazeutischer kaugummi mit acetylsalicylsaeure |
FR2708853A1 (fr) * | 1993-06-30 | 1995-02-17 | Salsarulo Gilles | Composition à base d'acide acétylsalicylique à biodisponibilité améliorée et procédé pour la produire. |
US5498426A (en) * | 1994-10-03 | 1996-03-12 | The Procter & Gamble Company | Liquid antacid compositions |
US6077539A (en) | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
UA95093C2 (uk) * | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Спосіб одержання кальцієвмісної сполуки |
JP5663238B2 (ja) * | 2009-08-31 | 2015-02-04 | ライオン株式会社 | 内服固形製剤及びその製造方法 |
-
1981
- 1981-08-05 CA CA000383212A patent/CA1165242A/en not_active Expired
-
1982
- 1982-05-20 NZ NZ200695A patent/NZ200695A/en unknown
- 1982-05-24 AU AU84109/82A patent/AU551510B2/en not_active Ceased
- 1982-05-26 GR GR68265A patent/GR75990B/el unknown
- 1982-06-28 PH PH27503A patent/PH18787A/en unknown
- 1982-06-30 PT PT75168A patent/PT75168B/pt not_active IP Right Cessation
- 1982-06-30 JP JP57111859A patent/JPS588020A/ja active Granted
- 1982-07-01 KR KR8202953A patent/KR880001933B1/ko active
- 1982-07-01 BE BE0/208511A patent/BE893729A/fr not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPS588020A (ja) | 1983-01-18 |
NZ200695A (en) | 1985-02-28 |
KR880001933B1 (ko) | 1988-10-04 |
AU8410982A (en) | 1983-01-06 |
PH18787A (en) | 1985-09-25 |
AU551510B2 (en) | 1986-05-01 |
KR840000239A (ko) | 1984-02-18 |
GR75990B (xx) | 1984-08-03 |
CA1165242A (en) | 1984-04-10 |
PT75168A (en) | 1982-07-01 |
BE893729A (fr) | 1983-01-03 |
PT75168B (en) | 1985-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4339428A (en) | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component | |
US4664915A (en) | Compressed and formed alkaline component suitable for use in buffered aspirin product | |
US4294819A (en) | Alkaline analgesic capsule | |
CA2311734C (en) | Flash-melt oral dosage formulation | |
US3146169A (en) | Pharmaceutical formulations and their manufacture | |
CA1073358A (en) | Sustained release formulations | |
US20080286344A1 (en) | Solid form | |
EP1737432A2 (en) | Orally disintegrating tablets and methods of manufacture | |
RU2398571C2 (ru) | Композиция, включающая ацетаминофен, кофеин и необязательно аспирин в смеси со щелочным агентом для увеличения абсорбции | |
RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
JP2009545557A (ja) | 胃保持性のデリバリーシステム | |
US20050031682A1 (en) | Modified calcium phosphate excipient | |
JP7198575B2 (ja) | メマンチン塩酸塩含有口腔内崩壊錠 | |
US5374430A (en) | Pharmaceutical formulation | |
JPH11199517A (ja) | 口腔内速崩壊性錠剤 | |
JPH0244286B2 (xx) | ||
JP4601271B2 (ja) | 圧縮成形製剤およびその製造方法 | |
JP6114573B2 (ja) | ロキソプロフェンナトリウムと制酸剤を含有する固形製剤 | |
JP4658306B2 (ja) | 錠剤用医薬組成物 | |
JP2010159289A (ja) | 圧縮成形製剤およびその製造方法 | |
MXPA00006125A (en) | Flash-melt oral dosage formulation |